Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
224.9 ^USD	+2.21%		+3.27%	-13.07%

May. 31	Biogen: Brussels grants marketing authorization for Charcot disease	CF
May. 31	Disaster averted

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.	May. 31	BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors	May. 30	BU
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB	May. 30	PR
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS	May. 30	GL
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS	May. 30	AQ
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors	May. 30	BU
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors	May. 30	BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	May. 30	BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	May. 30	PR
Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB	May. 28	BU
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea	May. 28	AQ
Biogen : “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea	May. 26	PU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	May. 23	PR
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors	May. 23	BU
BIIB Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	May. 23	BU
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm	May. 23	PR
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen	May. 23	PR
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences	May. 23	AQ
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	May. 23	BU
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers - BIIB	May. 22	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biogen Inc.

Equities

BIIB

US09062X1037

Press Releases

Filters